ID: ALA3397810

Max Phase: Preclinical

Molecular Formula: C25H25F2NO2

Molecular Weight: 409.48

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1ccc(CN[C@H]2CC[C@@H](C(c3ccc(F)cc3)c3ccc(F)cc3)OC2)cc1

Standard InChI:  InChI=1S/C25H25F2NO2/c26-20-7-3-18(4-8-20)25(19-5-9-21(27)10-6-19)24-14-11-22(16-30-24)28-15-17-1-12-23(29)13-2-17/h1-10,12-13,22,24-25,28-29H,11,14-16H2/t22-,24-/m0/s1

Standard InChI Key:  UDLPJHJXNMHWEW-UPVQGACJSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 409.48

Molecular Weight (Monoisotopic): 409.1853

AlogP: 5.14

#Rotatable Bonds: 6

Polar Surface Area: 41.49

Molecular Species: BASE

HBA: 3

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 3

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.60

CX Basic pKa: 8.80

CX LogP: 5.12

CX LogD: 3.99

Aromatic Rings: 3

Heavy Atoms: 30

QED Weighted: 0.59

Np Likeness Score: 0.04

References

1. Santra S, Sharma H, Vedachalam S, Antonio T, Reith M, Dutta A..  (2015)  Development of potent dopamine-norepinephrine uptake inhibitors (DNRIs) based on a (2S,4R,5R)-2-benzhydryl-5-((4-methoxybenzyl)amino)tetrahydro-2H-pyran-4-ol molecular template.,  23  (4): [PMID:25593099] [10.1016/j.bmc.2014.12.040]

Source

Source(1):

• Scientific Literature